E Jacqz-Aigrain
Overview
Explore the profile of E Jacqz-Aigrain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
1122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Facchin A, Benyoub N, Elie V, Magreault S, Jacqz-Aigrain E
Antimicrob Agents Chemother
. 2023 Mar;
67(4):e0159722.
PMID: 36880779
Valganciclovir, the ganciclovir prodrug, is an antiviral agent used to prevent cytomegalovirus infection in renal transplant children. Therapeutic drug monitoring is still necessary to ensure optimal therapeutic area under the...
2.
DAgate S, Musuamba F, Jacqz-Aigrain E, Pasqua O
Front Pharmacol
. 2021 Mar;
12:624662.
PMID: 33762945
The effectiveness of antibiotics for the treatment of severe bacterial infections in newborns in resource-limited settings has been determined by empirical evidence. However, such an approach does not warrant optimal...
3.
Bui S, Facchin A, Ha P, Bouchet S, Leroux S, Nacka F, et al.
J Antimicrob Chemother
. 2020 May;
75(8):2232-2239.
PMID: 32457995
Background: Pharmacokinetics data on ceftazidime are sparse for the paediatric population, particularly for children with cystic fibrosis (CF) or severe infections. Objectives: To characterize the population pharmacokinetics of ceftazidime in...
4.
Facchin A, Elie V, Benyoub N, Magreault S, Maisin A, Storme T, et al.
Antimicrob Agents Chemother
. 2019 Sep;
63(12).
PMID: 31527022
Background: Valganciclovir, the ganciclovir prodrug, is an antiviral agent administered orally to prevent or treat cytomegalovirus infection in solid organ transplant recipients. Dosing regimen of valganciclovir is still controversial in...
5.
Facchin A, Bui S, Leroux S, Nacka F, Koehl B, Maksoud E, et al.
J Antimicrob Chemother
. 2018 Sep;
73(12):3423-3429.
PMID: 30203024
Objectives: To determine the ciprofloxacin population pharmacokinetics in paediatric patients and the impact of underlying disease and evaluate the appropriateness of current dosage regimens. Patients And Methods: Plasma concentrations of...
6.
Leroux S, Jacqz-Aigrain E, Elie V, Legrand F, Guellec C, Aurich B, et al.
Br J Clin Pharmacol
. 2018 May;
84(9):1989-1999.
PMID: 29744900
Aims: The pharmacokinetics (PK) of fluconazole and micafungin differ in neonates compared with children and adults. Dosing instructions in product labels appear to be inconsistent with the emerging scientific evidence....
7.
Lancia P, Adam de Beaumais T, Jacqz-Aigrain E
Pharmacogenomics J
. 2017 Mar;
17(3):209-221.
PMID: 28349930
Many factors (physiological, pathological, environmental or genetic) are associated with variability in drug effect. Most patients respond to a standard treatment but the drug may be ineffective or toxic. In...
8.
Gouyon B, Iacobelli S, Saliba E, Quantin C, Pignolet A, Jacqz-Aigrain E, et al.
J Clin Pharm Ther
. 2016 Nov;
42(1):64-68.
PMID: 27882560
What Is Known: The neonatal intensive care units (NICUs) are at the highest risk of drug dose error of all hospital wards. NICUs also have the most complicated prescription modalities....
9.
Leroux S, Zhao W, Biran V, Jacqz-Aigrain E
Arch Pediatr
. 2016 Jul;
23(9):966-73.
PMID: 27451383
There is wide variation in neonatal dosages of antibiotics in clinical practice, both nationally and internationally. This reflects the lack of evaluation of drugs in this therapeutic class, although widely...
10.
Ramos-Martin V, Johnson A, Livermore J, McEntee L, Goodwin J, Whalley S, et al.
J Antimicrob Chemother
. 2016 Jan;
71(4):992-1002.
PMID: 26755499
Objectives: CoNS are the most common cause of neonatal late-onset sepsis. Information on the vancomycin pharmacokinetics/pharmacodynamics against CoNS is limited. The aim of this study was to characterize vancomycin pharmacokinetic/pharmacodynamic...